
Welcome to Cell & Gene Live – An interactive forum to discuss some of the most important technologies and trends impacting cell and gene therapies.
Throughout the year, our Chief Editor, Erin Harris, sits down with industry experts to discuss how biotechs can tackle some of today’s biggest challenges they may face in driving progress in the cell and gene therapy field. Even better, the audience gets ask questions during the presentation. Each Cell & Gene Live session is archived and can be accessed at any time by registered site users.
CAN INNOVATION DRIVE DOWN CELL THERAPY MANUFACTURING COSTS?
-
Can Innovation Drive Down Cell Therapy Manufacturing Costs?
The high cost of producing new cell and gene therapies is one of the largest issues facing the industry. After launching Kymriah and Yescarta, Novartis’ price tags were $475,000 and $375,000, respectively. Advancements in manufacturing are driving costs down, but not at the required pace.
THE FUTURE OF CRISPR-ENGINEERED STEM CELL THERAPIES
-
The Future of CRISPR-Engineered Stem Cell Therapies
To learn more about CRISPR gene editing, Cell and Gene Chief Editor, Erin Harris, sat down with Sadik Kassim, Chief Technical Officer at Vor Biopharma to discuss the benefits of CRISPR-engineered stem cell therapies, the challenges and feasible solutions, what’s next, and more.
- The History of CRISPR Gene Edited Therapies
- The Future of CRISPR-Engineered Stem Cell Therapies: 3 Clinical Trial Examples
- The Ethical Implications Of Editing A Genome
- The Challenges Associated With CRISPR Gene Editing
- The Patient Perspective Of CRISPR-Engineered Stem Cell Therapies
- The Future of CRISPR-Engineered Stem Cell Therapies: Adverse Effects In Clinical Trials
- The Future of CRISPR-Engineered Stem Cell Therapies: Technology & Platforms
- The Permanency Of Gene Therapy
- The Future of CRISPR-Engineered Stem Cell Therapies: Digestive Disease Studies
- The Misconceptions Of CRISPR Gene Edited Stem Cell Therapies
- Will CRISPR Change Modern Medicine?
- The Future of CRISPR-Engineered Stem Cell Therapies: Outsourcing vs. In-House
- What The Gene Therapy Sector Doesn't Understand About CRISPR?
- The Future of CRISPR-Engineered Stem Cell Therapies: Virtual Event Audience Q&A